These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-000166-13 A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer. not-yet-due
Ongoing 2004-000168-28 A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer not-yet-due
Not reported 2004-002355-14 A randomized, multicenter, open phase III study comparing the postoperative use of 2013-12-13 due-trials
Not reported 2004-003980-62 Prospective randomized multicenter study to prevent chemotherapy induced ovarian failure with the GnRH-Agonist Goserelin in young hormone insensitive breast cancer patients receiving anthracycline con... 2010-03-30 due-trials
Exempt 2004-004880-31 A multicentre phase I-II study to investigate the combination of bendamustine with weekly paclitaxel as first or second line therapy in patients with metastatic breast cancer 2011-05-05 not-yet-due
Not reported 2005-000074-51 A multicenter phase II study to determine the efficacy of capecitabine as first line monochemotherapy in patients with HER2 negative, medium-risk, metastatic breast cancer 2009-06-25 due-trials
Not reported 2005-001546-17 GeparQuattro: A randomized phase III study exploring the efficacy of Capecitabine given concomitantly or in sequence to EC - Doc with or without Trastuzumab as neoadjuvant treatment of primary breast ... 2012-08-01 due-trials
Listed as ongoing, but also has a completion date 2005-002084-85 A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatme... 2009-01-07 bad-data
Not reported 2005-002626-59 A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy 2006-12-31 due-trials
Completed, but no date 2005-005835-87 A randomized discontinuation phase II study to determine the efficacy of RAD001 in breast cancer patients with bone metastases bad-data
Not reported 2006-005834-19 A phase III trials program exploring the integration of Bevacizumab, Everolimus (RAD001), and Lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer 2015-10-15 due-trials
Not reported 2007-000124-41 Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) + sorafenib followed by paclitaxel (P) + sorafenib in women with previously untreated primary breast cancer 2012-01-02 due-trials
Not reported 2008-003995-23 An investigational randomized phase II-(III) study on epirubicin plus cyclophospamide (or CMF) vs nab-paclitaxel plus capecitabine as adjuvant chemotherapy for elderly non frail patients with an incre... 2014-01-24 due-trials
Not reported Terminated 2008-003997-17 A randomized phase III study to determine the efficacy of a taxane and bevacizumab with or without capecitabine as first line chemotherapy in patients with metastatic breast cancer 2012-10-05 due-trials
Not reported 2009-015122-11 A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in 2018-06-12 due-trials
Not reported Terminated 2010-023237-37 A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with HER2-positive metastatic breast cancer 2015-03-31 due-trials
Not reported 2011-000075-13 A multicenter non-randomized phase II study to evaluate nab-paclitaxel in metastatic breast cancer patients failing a solvent based taxane as (neo-)adjuvant treatment 2013-09-20 due-trials
Not reported 2011-000553-23 A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer 2013-07-30 due-trials
Not reported 2011-004704-38 Dual blockage with Afatinib and Trastuzumab as neooadjuvant treatment for patients with lo-cally advanced or operable breast cancer receiving taxane-anthracycline containing chemo-therapy (DAFNE study... 2014-02-19 due-trials
Ongoing 2011-005214-11 Neo- / adjuvant phase III trial to compare intense dose-dense chemotherapy to tailored dose-dense chemotherapy in patients with high-risk early breast cancer (GAIN-2 trial) not-yet-due
Not reported 2012-003330-16 Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or lumina... 2015-08-27 due-trials
Ongoing 2013-001040-62 Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk ... not-yet-due
Not reported 2014-000619-14 A randomized phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto) 2017-01-30 due-trials
Completed, but no date 2014-005126-35 A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer bad-data
Completed, but no date 2015-001755-72 Investigating Denosumab as an add-on to neoadjuvant chemotherapy in RANK/L-positive or RANK/L-negative primary breast cancer and two different nab-Paclitaxel schedules in a 2x2 factorial design (Gepar... bad-data
Completed, but no date 2015-002714-72 A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4736 to a taxane-anthracycline containing chemotherapy in triple negative breast cancer. bad-data
Not reported 2015-003509-41 A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients ... 2019-02-27 due-trials
Ongoing 2017-003667-35 Anti-hormonal maintenance treatment with the CDK4/6 inhibitor Ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial not-yet-due
Completed, but no date 2018-001155-13 A Phase III, Randomized, Open-Label Study Investigating the Addition of Durvalumab to an Anthracycline-Taxane based Chemotherapy in Early-Stage Triple-Negative Breast Cancer bad-data
Ongoing 2019-004100-35 Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatmen... not-yet-due